The mission of DTC/DTS focuses on developing novel diagnostics and therapies for cancer. These groups are working together to generate biomarkers and therapeutics that span initial research efforts through late-phase clinical trials. Clinicians, research nurses, and support staff from both groups have extensive experience with early-phase combination and single-agent studies and provide outstanding clinical care for patients with advanced malignancies. Over the past four years, DTC/DTS has continued to conduct early-phase clinical trials which have resulted in a number of publications and is coordinating several multicenter trials to open at leading drug development centers across the US.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Training Intramural Research (ZIE)
Project #
1ZIEBC011271-04
Application #
8763821
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2013
Total Cost
$1,016,675
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Kelly, Ronan J; Rajan, Arun; Force, Jeremy et al. (2011) Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. Clin Cancer Res 17:1190-9
Jain, Lokesh; Woo, Sukyung; Gardner, Erin R et al. (2011) Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol 72:294-305
Kummar, Shivaani; Gutierrez, Martin E; Gardner, Erin R et al. (2010) Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer 46:340-7
Jain, Lokesh; Sissung, Tristan M; Danesi, Romano et al. (2010) Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 29:95